Industry Contributor: Richard Kennedy, MD, Ph.D

Richard Kennedy, MD, Ph.D, is  McClay Professor in Medical Oncology, Queens University. Belfast and Vice President and Medical Director, Almac Diagnostics. He graduated in medicine from Queen?s University Belfast in 1995. In 2004 he was awarded a PhD in molecular biology from The Queen?s University of Belfast. From 2004-2007 he worked as an instructor in oncology at Harvard Medical School, USA, where he identified novel biomarkers and drug targets for cancer treatment.

In August 2007 he joined Almac Diagnostics where he is responsible for the internal research pipeline and for a CLIA compliant diagnostics laboratory that supports patient stratification in clinical trials. In June 2011 he joined the faculty of Queen?s University, Belfast where he directs a laboratory and hospital based research group focussed on various aspects of stratified medicine. Sloan is a Consultant Medical Oncologist at Belfast City Hospital and continues to manage cancer patients. He can be reached at Richard.kennedy@almacgroup.com

Content From This Contributor:

  • New Breast Cancer Chemo Response Test Predicts Benefit from DNA Damage-based Chemotherapy Drugs [Article]

Copyright ? 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.